Diabetes trials on SGLT2 and GLP1 and their effects on hypertension

Professor Peter Nilsson held a lecture on the cardiovascular effects of SGLT-2 inhibitors and GLP-1 agonists, the two new drug classes which revolutionized the treatment of type-2 diabetes at the recent Annual Congress of the European Society of Hypertension.  According to the results: - SGLT-2 inhibitors and GLP-1 receptor agonists are mostly safe, well-proven and effective drugs to prevent CVD complications and renal impairment/ events in type 2 diabetes patients at high or medium risk. - GLP-1 RAs are more effective than SGLT-2is to reduce bodyweight, but SGLT-2is are more effective than standard GLP-1 RAs to reduce office and ambulatory BP. -Recent guidelines suggest using SGLT-2i and GLP1 RA more frequently in patients at high cardiovascular risk, with or without metformin.

What is the optimal treatment of hypertension in diabetics? The ESH 2023 Hypertension Guidelines on Diabetes

Professor Josep Redon shares his insights on the special issues the European Society of Hypertension Guidelines covers, focusing on the best treatment options for patients with type-2 diabetes.

Hyperuricemia in hypertensive patients

Professor Claudio Borghi on the elevated uric acid levels in hypertension. Which patient should be treated, when and how?

Managing Hypertension in Real Practice: the New ESH2023 Hypertension Guidelines

Professor Gianfranco Parati shares his insight on the new ESH Hypertension guidelines, how we should better manage hypertension in our patients.

Hypertensive patients with diabetes: Are RAAS/Diuretic combinations the foundation of treatment?

The Rehabilitation of Beta-Blockers in the ESH Hypertension Guidelines

Professor Sverre Erik Kjeldsen explains how the role of the beta-blockers changed a in the new ESH Hypertension guideline.

Hypertensive patients with heart disease: What should be the preferred combination?

Professor Konstantinos Tsioufis highlights an important aspect of the new ESH Hypertension guideline: hypertension and cardiac diseases. How these are connected to each other? How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

When hypertension and dyslipidemia co-exist: How to decrease CV risk?

Dr. Vitoria Cunha explains what is the relationship and effect of hypertension and dyslipidemia on each other? Is it recommended to treat the two risk factors together? How could the combined treatment of the two risk factors be made more accepted and routine among treating physicians? From the perspective of patients, how is it appropriate to communicate the global cardiovascular risk factor management approach? In addition, how can their adherence be improved?

What has changed in the new ESH Hypertension Guidelines?

Professor Bryan Williams was the driving force behind the 2018 ESH/ESC Hypertension guideline. Many points - including the algorithm for drug therapy - represented a significant step forward for practicing physicians. What changes have been made in the recently presented and published guideline concerning the diagnosis of hypertension and its diagnostic possibilities? Have there been any changes in the treatment algorithm? Has any drug group received more emphasis?

Hypertension in women - an underrecognized issue

Professor Renata Cifkova was responsible in the new ESH Hypertension guideline for the topic of hypertension in women. In the interview, she explained what clinicians should know about this important topic.

The development of hypertension guidelines

Professor Neil Poulter share his insights on the development of guidelines and the treatment in general in the last 15 years, and the practical application of new guidelines.

Where is the role of triple combination in the management of hypertension?

Professor Reinhold Kreutz shares his insights about the antihypertensive triple fixed combinations.What pathophysiological bases justify the use of triple fixed combinations? How does the newly published guidelines determine the place of triple fixed combinations?

Hot questions on blood pressure measurement in clinical practice

Professor Paolo Palatini chaired a very interesting session at the ESH 2023 about the hot questions on blood pressure measurement.  - How to best perform office blood pressure management?  - How to measure blood pressure in the very obese patients? - Should ABPM parameters have a role in clinical practice?  - How to manage masked and masked uncontrolled hypertension?  - How to manage isolated systolic hypertension in the young?

Hypertension and kidney - the intricate relationship

Professor Pantelis Sarafidis shared his insights on kidney disease and hypertension,  and what the new ESH guidelines said about the management the hypertension people with chronic kidney disease.

Antihypertensive Drugs and Treatment Algorithms in the ESH2023 Hypertension Guidelines

Professor Michel Burnier presented the general aspects of the new European Society of Hypertension guidelines at ESH 2023. What are the major changes?

Beyond the algorithm: What combination to choose in hypertension treatment?

Professor Martin Strauss explains the preferred treatment of hypertension with a preferred RAAS blockade inhibitors. What kind of pill combination to choose?